Karvezide: Uses, Dosage & Side Effects
A fixed-dose combination of irbesartan (angiotensin II receptor blocker) and hydrochlorothiazide (thiazide diuretic) for the treatment of essential hypertension
Karvezide is a prescription combination medication containing two active substances: irbesartan (150 mg), an angiotensin II receptor blocker (ARB), and hydrochlorothiazide (12.5 mg), a thiazide diuretic. It is used to treat essential hypertension (high blood pressure) in adults whose blood pressure is not adequately controlled by either irbesartan or hydrochlorothiazide alone. The combination provides complementary blood pressure–lowering effects: irbesartan blocks the vasoconstrictive and aldosterone-secreting actions of angiotensin II, while hydrochlorothiazide promotes renal excretion of sodium and water to reduce blood volume. Karvezide is taken once daily as an oral tablet and has been shown in large clinical trials to significantly reduce blood pressure and provide end-organ protection, including renal benefits in patients with type 2 diabetes and hypertension.
Quick Facts: Karvezide
Key Takeaways
- Karvezide combines irbesartan (an angiotensin II receptor blocker) with hydrochlorothiazide (a thiazide diuretic) to provide greater blood pressure reduction than either agent alone, and is indicated for adults whose hypertension is not adequately controlled by monotherapy.
- The medication is taken once daily as a film-coated tablet, preferably in the morning, and can be taken with or without food, making it a convenient treatment option for long-term blood pressure management.
- Karvezide must not be used during pregnancy due to the risk of serious fetal harm, including renal failure and skeletal abnormalities, particularly during the second and third trimesters.
- Common side effects include dizziness, fatigue, and nausea; important drug interactions exist with lithium, NSAIDs, potassium supplements, and other renin-angiotensin system (RAS) blockers such as ACE inhibitors and aliskiren.
- Large clinical trials, including the IRMA-2 and IDNT studies, have demonstrated that irbesartan provides significant renal protective benefits in patients with type 2 diabetes and hypertension, reducing the progression of kidney disease beyond what can be attributed to blood pressure lowering alone.
What Is Karvezide and What Is It Used For?
Karvezide belongs to a well-established class of combination antihypertensive medications that pair an angiotensin II receptor blocker (ARB) with a thiazide diuretic. This combination strategy is widely recommended by international hypertension guidelines, including those from the European Society of Hypertension (ESH), the European Society of Cardiology (ESC), and the World Health Organization (WHO), as a preferred approach for patients who require more than one medication to achieve their blood pressure targets. Marketed under the brand names Karvezide and CoAprovel in Europe and Avalide in the United States, this combination has been available for more than two decades and has an extensive clinical evidence base supporting its efficacy and safety.
The first active ingredient, irbesartan, is a potent and selective angiotensin II type 1 (AT1) receptor antagonist. Angiotensin II is a powerful vasoconstrictor hormone produced by the renin-angiotensin-aldosterone system (RAAS), which plays a central role in blood pressure regulation, fluid balance, and cardiovascular remodeling. When angiotensin II binds to AT1 receptors on blood vessels, it causes vasoconstriction (narrowing of blood vessels), which raises blood pressure. Angiotensin II also stimulates the adrenal cortex to release aldosterone, a hormone that causes the kidneys to retain sodium and water, further increasing blood volume and pressure. Irbesartan selectively blocks the AT1 receptor, preventing angiotensin II from exerting these effects. This leads to vasodilation, reduced aldosterone secretion, and ultimately a reduction in blood pressure. Unlike ACE inhibitors, which also target the RAAS, irbesartan does not inhibit the enzyme that breaks down bradykinin, which is why ARBs are associated with a significantly lower incidence of dry cough – a common side effect that causes many patients to discontinue ACE inhibitor therapy.
The second active ingredient, hydrochlorothiazide (HCTZ), is a thiazide diuretic that has been used in clinical practice since the 1950s and remains one of the most widely prescribed antihypertensive medications worldwide. Hydrochlorothiazide acts on the distal convoluted tubule of the kidney, where it inhibits the sodium-chloride cotransporter (NCC), reducing the reabsorption of sodium and chloride. This increases the excretion of sodium, chloride, and water in the urine, leading to a reduction in extracellular fluid volume and plasma volume. The initial blood pressure–lowering effect of hydrochlorothiazide is primarily due to this volume reduction. However, with chronic use, the plasma volume partially returns to normal, and the sustained antihypertensive effect is thought to be mediated by a reduction in peripheral vascular resistance, possibly through changes in vascular smooth muscle calcium handling and changes in local vasoactive substances.
The combination of irbesartan and hydrochlorothiazide is pharmacologically rational because the two agents act through distinct but complementary mechanisms. Hydrochlorothiazide activates the RAAS by reducing blood volume, which in turn stimulates renin release and angiotensin II production. This compensatory RAAS activation can partially offset the blood pressure–lowering effect of the diuretic when used alone. By adding irbesartan, which blocks the AT1 receptor, this compensatory mechanism is effectively neutralized, resulting in an additive or synergistic blood pressure reduction. Furthermore, the RAAS-blocking effect of irbesartan counteracts the hypokalemic (low potassium) tendency of hydrochlorothiazide by reducing aldosterone-mediated potassium excretion, although monitoring of serum potassium remains important.
Karvezide is indicated for the treatment of essential hypertension in adults. Essential (primary) hypertension is the most common form of high blood pressure, accounting for approximately 90–95% of all hypertension cases. It develops gradually over many years and is associated with multiple risk factors including age, family history, obesity, physical inactivity, excessive sodium intake, and chronic stress. Uncontrolled hypertension is a major risk factor for cardiovascular disease, stroke, heart failure, chronic kidney disease, and premature death. The WHO estimates that hypertension contributes to approximately 7.5 million deaths worldwide annually, making it the single largest risk factor for global mortality.
Karvezide is specifically intended for patients whose blood pressure is not adequately controlled by irbesartan or hydrochlorothiazide alone, or as initial therapy in patients who are likely to need two medications to achieve their blood pressure goal. International guidelines now recommend initial combination therapy for many patients with hypertension, particularly those with grade 2 hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg) or those at high cardiovascular risk. The ESH/ESC 2023 guidelines specifically recommend ARB/diuretic combinations as one of the preferred dual-therapy options for hypertension management.
Beyond its blood pressure–lowering effects, irbesartan has demonstrated significant renal protective benefits in landmark clinical trials. The IRMA-2 (Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria) study showed that irbesartan 300 mg reduced the progression from microalbuminuria to overt proteinuria by 70% in patients with type 2 diabetes and hypertension. The IDNT (Irbesartan Diabetic Nephropathy Trial) demonstrated that irbesartan reduced the risk of doubling of serum creatinine, end-stage renal disease, or death from any cause by 20% compared with placebo and 23% compared with amlodipine. These renal protective effects were independent of blood pressure reduction, suggesting a direct protective effect of AT1 receptor blockade on the kidney.
What Should You Know Before Taking Karvezide?
Contraindications
Karvezide must not be used in the following situations:
- Hypersensitivity: Do not use Karvezide if you are allergic to irbesartan, hydrochlorothiazide, or any of the other ingredients in the tablet. Because hydrochlorothiazide is a sulfonamide derivative, patients with a known allergy to sulfonamides or sulfonamide-derived drugs may also be at risk of cross-reactivity and should not take Karvezide.
- Pregnancy (second and third trimesters): Karvezide is absolutely contraindicated during the second and third trimesters of pregnancy. Use during the first trimester is also not recommended. ARBs can cause serious and potentially fatal harm to the developing fetus, including renal failure, oligohydramnios (reduced amniotic fluid), skull ossification defects, hypotension, and hyperkalemia in the neonate.
- Severe renal impairment: Karvezide should not be used in patients with severe renal impairment (creatinine clearance <30 mL/min) because hydrochlorothiazide is ineffective as a diuretic at this level of kidney function and may accumulate to toxic levels.
- Anuria: Karvezide is contraindicated in patients with anuria (inability to produce urine).
- Severe hepatic impairment, biliary cirrhosis, or cholestasis: Hydrochlorothiazide is hepatically cleared in part and may cause electrolyte disturbances that can precipitate hepatic coma in patients with severely impaired liver function.
- Refractory hypokalemia or hypercalcemia: Thiazide diuretics can worsen these electrolyte abnormalities.
- Concomitant use with aliskiren in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR <60 mL/min/1.73 m²): Dual RAAS blockade significantly increases the risk of hypotension, hyperkalemia, and renal impairment.
Warnings and Precautions
Karvezide must not be used during pregnancy. Angiotensin II receptor blockers can cause serious harm to the developing fetus, including kidney damage, reduced amniotic fluid, skull defects, and fetal death. If you become pregnant while taking Karvezide, stop the medication immediately and contact your doctor. Women of childbearing potential must use effective contraception during treatment.
Before starting Karvezide, inform your doctor if you have any of the following conditions, as they may require special monitoring or dose adjustments:
- Renal artery stenosis: Medications that affect the RAAS can cause significant deterioration of renal function in patients with unilateral or bilateral renal artery stenosis. Monitor renal function closely if this condition is suspected.
- Kidney disease: Periodic monitoring of serum creatinine, potassium, and uric acid is recommended in patients with renal impairment. The hydrochlorothiazide component may accumulate and the diuretic response may be reduced in patients with impaired renal function.
- Heart failure: ARBs can cause hypotension in patients with heart failure, particularly those who are volume- or salt-depleted from diuretic therapy. Start with a lower dose and monitor closely.
- Volume or sodium depletion: Patients who are volume-depleted (e.g., from vomiting, diarrhea, high-dose diuretic therapy, or strict salt restriction) may experience symptomatic hypotension when starting Karvezide. Correct volume depletion before initiating therapy or start with a lower dose.
- Diabetes mellitus: Hydrochlorothiazide may impair glucose tolerance and increase blood sugar levels. Diabetic patients may require adjustment of insulin or oral hypoglycemic medication doses. The combination with aliskiren is contraindicated in diabetic patients.
- Gout: Hydrochlorothiazide can increase serum uric acid levels and may precipitate gout attacks in predisposed individuals.
- Systemic lupus erythematosus (SLE): Hydrochlorothiazide has been reported to activate or exacerbate SLE.
- Photosensitivity: Hydrochlorothiazide can cause photosensitivity reactions. Use sun protection and avoid prolonged sun exposure or tanning beds. If a photosensitivity reaction occurs, discontinue the medication.
- Electrolyte imbalances: Hydrochlorothiazide can cause hyponatremia (low sodium), hypokalemia (low potassium), hypomagnesemia (low magnesium), and hypercalcemia (high calcium). Regular monitoring of electrolytes is recommended, particularly during the first few months of treatment and in elderly patients.
Pregnancy and Breastfeeding
Karvezide is contraindicated during pregnancy. If pregnancy is detected, treatment must be discontinued as soon as possible. Direct effects of medications acting on the RAAS on the fetus include renal failure, oligohydramnios, skull ossification retardation, neonatal hypotension, hyperkalemia, and death. Additionally, hydrochlorothiazide crosses the placenta and may cause fetal or neonatal thrombocytopenia, jaundice, and electrolyte disturbances. Women of childbearing potential should be counseled about the risks and should use reliable contraception throughout treatment.
Irbesartan is excreted in the milk of lactating rats, but it is not known whether it passes into human breast milk. Hydrochlorothiazide is excreted in human breast milk in small amounts. Due to the potential for adverse effects in the breastfed infant, Karvezide is not recommended during breastfeeding. Alternative antihypertensive medications with better-established safety profiles during breastfeeding should be considered.
Driving and Operating Machinery
No studies on the effects of Karvezide on the ability to drive or use machines have been performed. However, based on its pharmacological properties, Karvezide is unlikely to affect these abilities in most patients. Dizziness and fatigue can occur, particularly at the start of treatment or when the dose is increased. Patients should be advised to exercise caution until they know how Karvezide affects them personally. If dizziness or lightheadedness occurs, patients should avoid driving or operating machinery until the symptoms resolve.
How Does Karvezide Interact with Other Drugs?
As a combination product containing two pharmacologically active substances, Karvezide has a more complex drug interaction profile than either component used alone. The interactions arise from both the irbesartan (ARB) component and the hydrochlorothiazide (thiazide diuretic) component, and in some cases from the combined effects of both agents. Understanding these interactions is essential for safe prescribing and patient monitoring.
Major Interactions
| Drug / Drug Class | Interaction | Clinical Significance |
|---|---|---|
| Lithium | Both irbesartan and HCTZ reduce renal lithium clearance, increasing serum lithium levels | Risk of lithium toxicity. Combination not recommended; if necessary, monitor lithium levels closely |
| ACE inhibitors (enalapril, ramipril, lisinopril) | Dual RAAS blockade increases risk of hypotension, hyperkalemia, and renal impairment | Avoid combination. Contraindicated in patients with diabetes or renal impairment (GFR <60) |
| Aliskiren | Dual RAAS blockade with increased risk of adverse renal and cardiovascular events | Contraindicated in patients with diabetes or moderate-to-severe renal impairment |
| NSAIDs (ibuprofen, naproxen, diclofenac) | NSAIDs reduce antihypertensive effect and increase risk of acute kidney injury | Use with caution. Monitor blood pressure and renal function. Avoid prolonged concomitant use |
| Potassium supplements / potassium-sparing diuretics | Irbesartan reduces aldosterone, causing potassium retention; risk of hyperkalemia when combined with potassium sources | Monitor serum potassium frequently. Use potassium supplements with caution |
Other Notable Interactions
| Drug / Drug Class | Interaction | Recommendation |
|---|---|---|
| Digoxin | HCTZ-induced hypokalemia increases sensitivity to digitalis toxicity | Monitor potassium and digoxin levels |
| Antidiabetic medications (insulin, metformin, sulfonylureas) | HCTZ may impair glucose tolerance, reducing efficacy of antidiabetic drugs | Monitor blood glucose; dose adjustment may be needed |
| Corticosteroids, ACTH | Increased risk of electrolyte depletion, particularly hypokalemia | Monitor electrolytes |
| Carbamazepine | Increased risk of hyponatremia when combined with HCTZ | Monitor sodium levels |
| Cholestyramine / colestipol | Reduces absorption of HCTZ from the gastrointestinal tract | Take Karvezide at least 1 hour before or 4–6 hours after resin |
| Alcohol, barbiturates, opioids | May potentiate orthostatic hypotension caused by HCTZ | Rise slowly from sitting or lying positions; limit alcohol intake |
Irbesartan is primarily metabolized by CYP2C9 in the liver, but it does not significantly inhibit or induce major cytochrome P450 enzymes. No clinically relevant pharmacokinetic interactions have been observed between irbesartan and commonly co-prescribed medications including warfarin, digoxin, nifedipine, or simvastatin in dedicated interaction studies. Hydrochlorothiazide is not significantly metabolized and is excreted largely unchanged by the kidneys, so hepatic drug interactions are not expected with the HCTZ component.
Combining Karvezide with an ACE inhibitor (such as enalapril, ramipril, or lisinopril) or with aliskiren results in dual blockade of the renin-angiotensin-aldosterone system. This significantly increases the risk of hypotension, hyperkalemia, and acute kidney injury. The ONTARGET trial demonstrated that dual RAAS blockade with an ARB and ACE inhibitor increased adverse events without additional cardiovascular benefit. This combination is contraindicated in patients with diabetes or moderate-to-severe renal impairment and is generally not recommended for any patient.
What Is the Correct Dosage of Karvezide?
Karvezide should always be used exactly as prescribed by your doctor. The tablets are designed for once-daily oral administration, and consistency in timing is important for optimal 24-hour blood pressure control. Most healthcare providers recommend taking Karvezide in the morning because the hydrochlorothiazide component increases urine output, which could be disruptive if the medication is taken in the evening. However, the timing should be individualized based on your blood pressure profile and your doctor’s recommendation.
Adults
| Patient Group | Recommended Dose | Maximum Dose | Notes |
|---|---|---|---|
| Standard adult dose | 150/12.5 mg once daily | 300/25 mg once daily | Take at the same time each day, preferably morning |
| After inadequate response to 150/12.5 mg | 300/12.5 mg once daily | 300/25 mg once daily | Titrate upward at 2–4 week intervals |
| Patients with volume depletion | Correct volume status first | — | Start with irbesartan monotherapy initially |
| Mild-to-moderate renal impairment | No dose adjustment needed | 300/25 mg once daily | Monitor renal function and electrolytes |
Treatment with Karvezide is usually initiated after patients have been stabilized on either irbesartan or hydrochlorothiazide as monotherapy and have not achieved adequate blood pressure control. In some cases, particularly in patients with grade 2 or 3 hypertension (systolic ≥160 mmHg or diastolic ≥100 mmHg) or those at high cardiovascular risk, the doctor may prescribe Karvezide as the initial antihypertensive medication, bypassing the monotherapy step. This approach is supported by current ESH guidelines, which recommend initial combination therapy for most patients with hypertension to achieve faster and more effective blood pressure control.
The tablets should be swallowed whole with a glass of water. They can be taken with or without food, as food does not significantly affect the absorption of either irbesartan or hydrochlorothiazide. Do not crush, break, or chew the film-coated tablets.
Children and Adolescents
Karvezide is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of the irbesartan/hydrochlorothiazide combination have not been established in this age group. Pediatric hypertension requires specialized evaluation and management with medications that have been specifically studied in children.
Elderly Patients
No dose adjustment is required for elderly patients, although therapy should generally be initiated at the lowest available dose and titrated gradually. Elderly patients may be more susceptible to the hypotensive effects of Karvezide, particularly if they are volume-depleted or taking multiple medications. Renal function and electrolytes should be monitored more frequently in elderly patients, as age-related decline in renal function is common and may affect the clearance of hydrochlorothiazide.
Missed Dose
If you forget to take your daily dose of Karvezide, take it as soon as you remember on the same day. If it is already close to the time for your next dose, skip the missed dose and take the next dose at the usual time. Do not take a double dose to make up for the one you forgot. Missing a single dose is unlikely to cause a significant rise in blood pressure, but regular daily dosing is essential for sustained blood pressure control. Consider setting a daily alarm or keeping your medication in a visible location to help with adherence.
Overdose
If you take more Karvezide than prescribed, contact your doctor or poison control center immediately, or go to the nearest hospital emergency department. Overdose symptoms are likely to include marked hypotension (dangerously low blood pressure), tachycardia or bradycardia (abnormal heart rate), and dehydration from excessive diuresis with electrolyte abnormalities. Treatment is symptomatic and supportive: the patient should be placed in the supine position with legs elevated, intravenous saline infusion should be considered to restore volume, and electrolytes (particularly potassium and sodium) should be monitored and corrected. Irbesartan is not dialyzable due to its high protein binding. Hydrochlorothiazide is partially dialyzable.
What Are the Side Effects of Karvezide?
Like all medicines, Karvezide can cause side effects, although not everyone will experience them. The side effect profile reflects the combined effects of both the irbesartan and hydrochlorothiazide components. Overall, the combination is well tolerated in clinical trials, with a discontinuation rate due to adverse events comparable to placebo. Many side effects are dose-related and may resolve spontaneously as the body adjusts to the medication over the first few weeks of treatment.
The following side effects have been reported in clinical trials and post-marketing surveillance. They are classified by frequency according to international convention:
Common
May affect up to 1 in 10 people
- Dizziness or lightheadedness
- Nausea or vomiting
- Fatigue
- Abnormal urination (increased frequency or volume)
- Increases in blood urea nitrogen (BUN) and creatinine
- Increases in creatine kinase
Uncommon
May affect up to 1 in 100 people
- Orthostatic hypotension (dizziness or fainting upon standing)
- Tachycardia (rapid heartbeat)
- Facial flushing or edema
- Swelling of extremities (peripheral edema)
- Sexual dysfunction
- Headache
- Musculoskeletal pain
- Hyperkalemia (elevated blood potassium)
- Hypokalemia (low blood potassium, from HCTZ)
- Hyperuricemia (elevated uric acid)
- Hyponatremia (low blood sodium)
Rare
May affect up to 1 in 1,000 people
- Jaundice (yellowing of skin or eyes)
- Hepatitis (liver inflammation)
- Impaired renal function
- Pancreatitis (inflammation of the pancreas)
Not Known
Frequency cannot be estimated from available data
- Angioedema (swelling of face, lips, tongue, or throat)
- Rash, urticaria (hives)
- Thrombocytopenia (low platelet count)
- Hypersensitivity vasculitis
- Hypomagnesemia (low magnesium)
- Non-melanoma skin cancer (associated with long-term HCTZ use: basal cell carcinoma, squamous cell carcinoma)
- Acute angle-closure glaucoma
- Choroidal effusion
Electrolyte disturbances are among the most clinically important side effects to monitor. Hydrochlorothiazide can cause hypokalemia (low potassium), which may manifest as muscle weakness, cramps, fatigue, or cardiac arrhythmias. However, the potassium-sparing effect of irbesartan (through aldosterone reduction) partially counteracts this tendency, resulting in a more neutral potassium balance than with hydrochlorothiazide alone. Nevertheless, regular monitoring of serum potassium is recommended, particularly in elderly patients, patients with renal impairment, and those taking other medications that affect potassium levels.
Hydrochlorothiazide has been associated with an increased risk of non-melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma) with cumulative long-term use. This risk appears to be dose-dependent and related to the photosensitizing properties of HCTZ. Patients taking Karvezide for prolonged periods should be advised to limit UV exposure, use sunscreen, and have regular skin examinations. Any new or changing skin lesions should be reported to a healthcare provider for evaluation.
Metabolic effects of hydrochlorothiazide include impaired glucose tolerance and increases in total cholesterol, LDL cholesterol, and triglycerides. These effects are generally modest at the low dose of 12.5 mg contained in Karvezide and are less pronounced than with higher doses of HCTZ. Irbesartan has been shown to have a neutral or slightly beneficial effect on metabolic parameters, which may partially offset the metabolic effects of HCTZ.
Contact your doctor immediately if you experience signs of a severe allergic reaction (swelling of face, lips, tongue, or throat; difficulty breathing; severe rash), signs of severe electrolyte imbalance (muscle cramps, weakness, irregular heartbeat, confusion, excessive thirst), significantly reduced urine output, or symptoms of liver problems (yellowing of skin or eyes, dark urine, persistent nausea). If you experience severe dizziness or fainting, lie down and seek medical attention.
How Should You Store Karvezide?
Proper storage of Karvezide ensures the medication maintains its full potency and safety throughout its shelf life. Unlike biological medications that require refrigeration, Karvezide is a stable oral tablet formulation that can be stored at standard room temperature conditions.
- Temperature: Store below 30°C (86°F). Avoid exposure to excessive heat or direct sunlight. Do not refrigerate or freeze.
- Moisture protection: Keep the tablets in the original blister package until ready to use. The film coating provides some moisture protection, but prolonged exposure to humidity can affect the tablet integrity. Do not transfer tablets to a pill box for extended periods in humid environments.
- Keep out of reach of children: Store in a secure location where children and pets cannot access the medication.
- Expiration date: Do not use Karvezide after the expiration date printed on the blister pack and outer carton. The expiration date refers to the last day of that month.
- Inspection: Before taking each tablet, briefly inspect it for any visible damage, discoloration, or unusual appearance. If the tablet appears significantly different from usual, consult your pharmacist.
- Disposal: Do not throw away unused medications via household waste or down the drain. Return unused or expired tablets to your pharmacy for proper disposal in accordance with local regulations.
When traveling, keep Karvezide in your carry-on luggage rather than checked baggage to avoid extreme temperature exposure in aircraft cargo holds. Bring an adequate supply plus extra tablets in case of travel delays. Keep the medication in its original packaging and carry a copy of your prescription for international travel.
What Does Karvezide Contain?
Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to specific pharmaceutical ingredients. Below is a detailed breakdown of the active and inactive ingredients in Karvezide.
Active Ingredients
Each film-coated tablet contains:
- Irbesartan 150 mg – An angiotensin II type 1 (AT1) receptor antagonist. Irbesartan is a non-peptide, chemically synthesized compound with the molecular formula C25H28N6O and a molecular weight of 428.5 g/mol. It is a white to off-white crystalline powder that is practically insoluble in water but freely soluble in common organic solvents.
- Hydrochlorothiazide 12.5 mg – A benzothiadiazine (thiazide) diuretic. Hydrochlorothiazide has the molecular formula C7H8ClN3O4S2 and a molecular weight of 297.7 g/mol. It is a white or practically white, crystalline powder that is slightly soluble in water.
Inactive Ingredients (Excipients)
| Ingredient | Role | Notes |
|---|---|---|
| Irbesartan | Active substance (ARB) | 150 mg per tablet |
| Hydrochlorothiazide | Active substance (thiazide diuretic) | 12.5 mg per tablet |
| Lactose monohydrate | Filler / diluent | Contains lactose – inform doctor if lactose intolerant |
| Microcrystalline cellulose | Filler / binder | Provides tablet structure |
| Croscarmellose sodium | Disintegrant | Helps tablet dissolve in GI tract |
| Hypromellose | Film-coating agent | Protective coating |
| Silicon dioxide (colloidal) | Glidant | Improves powder flow during manufacturing |
| Magnesium stearate | Lubricant | Prevents tablet sticking to machinery |
| Titanium dioxide (E171) | Colorant (film coating) | Provides white/opaque appearance |
| Macrogol 3000 | Film-coating plasticizer | Makes coating flexible |
| Iron oxide red and yellow (E172) | Colorants (film coating) | Gives tablet its peach color |
Appearance and Pack Sizes
Karvezide 150/12.5 mg tablets are peach-colored, biconvex, oval-shaped film-coated tablets with a heart debossed on one side and the number “2775” engraved on the other side. They are supplied in blister packs containing 14, 28, 56, or 98 tablets. Not all pack sizes may be marketed in every country.
Marketing Authorization Holder and Manufacturer
Karvezide is manufactured by Sanofi Winthrop Industrie (Ambares, France) and marketed by Sanofi. In the European Union, the marketing authorization is held by Sanofi-Aventis Groupe. The same combination is marketed under the brand name CoAprovel in many European countries and as Avalide in the United States and other markets. Generic versions containing irbesartan/hydrochlorothiazide are also widely available following patent expiration.
Frequently Asked Questions About Karvezide
Karvezide and CoAprovel contain exactly the same active ingredients (irbesartan and hydrochlorothiazide) at the same strengths and are manufactured by the same pharmaceutical company, Sanofi. The difference is solely in the brand name used in different markets. Karvezide is the trade name used in certain European countries, while CoAprovel is used in others. In the United States, the same combination is marketed as Avalide. The clinical effects, dosing, and safety profile are identical regardless of the brand name.
Alcohol can potentiate the blood pressure–lowering effect of Karvezide and increase the risk of orthostatic hypotension (dizziness or fainting when standing up). While moderate alcohol consumption is not absolutely contraindicated, it is advisable to limit alcohol intake while taking Karvezide, particularly when starting the medication or after a dose increase. If you do consume alcohol, rise slowly from sitting or lying positions and be aware of signs of low blood pressure such as dizziness or lightheadedness. Excessive alcohol intake should be avoided as it can independently raise blood pressure and counteract the benefits of antihypertensive treatment.
Karvezide is not typically associated with weight gain. In fact, the hydrochlorothiazide component is a diuretic that may cause a slight initial weight loss due to fluid loss. ARBs like irbesartan are considered weight-neutral medications. However, any initial weight change from fluid loss usually stabilizes within a few weeks. If you notice significant unexplained weight changes while taking Karvezide, discuss this with your doctor, as it could indicate fluid retention or other underlying conditions that need attention.
No, you should not stop taking Karvezide without consulting your doctor, even if your blood pressure readings are normal. Normal blood pressure readings while on medication indicate that the medication is working effectively. Stopping the medication abruptly will likely cause your blood pressure to rise again, which increases your risk of heart attack, stroke, and kidney damage. Hypertension is typically a lifelong condition that requires ongoing treatment. If you are concerned about taking medication long-term, discuss with your doctor whether lifestyle modifications (diet, exercise, weight loss, sodium reduction) might allow for a carefully supervised dose reduction in the future.
Yes, the irbesartan component of Karvezide has well-documented renal protective properties, particularly in patients with type 2 diabetes and hypertension. Landmark clinical trials (IRMA-2 and IDNT) demonstrated that irbesartan significantly reduced the progression of kidney disease in diabetic patients, including a 70% reduction in progression from microalbuminuria to overt proteinuria (IRMA-2) and a 20% reduction in the combined endpoint of doubling of serum creatinine, end-stage renal disease, or death (IDNT). These renal protective benefits were independent of blood pressure reduction, suggesting a direct protective effect of AT1 receptor blockade on kidney tissue. This makes Karvezide a particularly appropriate choice for hypertensive patients with type 2 diabetes and early kidney disease.
The increased urination is caused by the hydrochlorothiazide (HCTZ) component of Karvezide, which is a diuretic (sometimes called a “water pill”). HCTZ works by blocking sodium reabsorption in the kidneys, causing increased excretion of sodium, chloride, and water in the urine. This diuretic effect is most pronounced during the first few hours after taking the medication, which is why it is typically recommended to take Karvezide in the morning. The increased urination usually becomes less noticeable after the first few weeks of treatment as your body adjusts. If the increased urination is significantly disruptive, discuss the timing of your dose with your doctor.
References
- European Medicines Agency (EMA). Karvezide (irbesartan/hydrochlorothiazide) – Summary of Product Characteristics. Last updated 2025. Available at: EMA Karvezide EPAR.
- U.S. Food and Drug Administration (FDA). Avalide (irbesartan/hydrochlorothiazide) – Prescribing Information. Sanofi-Aventis. Revised 2024.
- Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878. doi:10.1056/NEJMoa011489. (IRMA-2 Trial)
- Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860. doi:10.1056/NEJMoa011303. (IDNT Trial)
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874–2071. doi:10.1097/HJH.0000000000003480.
- World Health Organization (WHO). Guideline for the pharmacological treatment of hypertension in adults. 2021. Available at: WHO Hypertension Guideline.
- ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559. doi:10.1056/NEJMoa0801317.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127–e248.
- British National Formulary (BNF). Irbesartan with hydrochlorothiazide. National Institute for Health and Care Excellence (NICE). 2025.
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. doi:10.1093/eurheartj/ehy339.
About Our Medical Team
All content on iMedic is created and reviewed by qualified medical professionals following international evidence-based guidelines. Our editorial process ensures accuracy, currency, and clinical relevance.
Medical Content Team
Specialists in cardiology, internal medicine, and clinical pharmacology with extensive experience in hypertension management and cardiovascular pharmacotherapy.
Medical Review Board
Independent panel of board-certified physicians who verify all medical claims against current evidence and international guidelines (WHO, EMA, FDA, ESC/ESH).
Editorial Standards
All content follows the GRADE evidence framework and is based on Level 1A evidence from systematic reviews and randomized controlled trials where available.
Independence
iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent, ensuring unbiased medical information for patients and caregivers.